As of the end of 2023, nearly 40 million people worldwide were living with HIV, including approximately 1.2 million in the ...

Vaccine makers were hit particularly hard yesterday, as Marks’ resignation letter alluded to disagreements with HHS Secretary ...

NORTHAMPTON, MA / ACCESS Newswire / April 1, 2025 / In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...

Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can ...

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...